To hear about similar clinical trials, please enter your email below
Trial Title:
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT ID:
NCT00616785
Condition:
Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Irinotecan
Etoposide
Conditions: Keywords:
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Unknown status
Study design:
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
cisplatin
Intervention type:
Drug
Intervention name:
etoposide
Intervention type:
Drug
Intervention name:
irinotecan hydrochloride
Intervention type:
Radiation
Intervention name:
radiation therapy
Summary:
RATIONALE: Drugs used in chemotherapy, such as irinotecan, cisplatin, and etoposide work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Radiation therapy uses high-energy x-rays to damage tumor
cells. Giving combination chemotherapy together with radiation therapy may kill more
tumor cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy
together with radiation therapy works in treating patients with stage III non-small cell
lung cancer that cannot be removed by surgery.
Detailed description:
OBJECTIVES:
Primary
- To evaluate the efficacy of induction chemotherapy comprising irinotecan
hydrochloride and cisplatin in patients with locally advanced, unresectable stage
III non-small cell lung cancer.
- To evaluate the feasibility of radiotherapy administered concurrently with etoposide
and cisplatin chemotherapy after induction chemotherapy in these patients.
Secondary
- To evaluate the toxicity of induction chemotherapy comprising irinotecan
hydrochloride and cisplatin in these patients.
- To assess whether this induction chemotherapy regimen will improve patient survival
when compared with outcomes from the predecessor study, SWOG-9019.
OUTLINE: Patients receive dose-dense induction chemotherapy comprising irinotecan
hydrochloride IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up
to 2 courses.
After completion of induction chemotherapy, patients undergo radiotherapy five days a
week for approximately 7 weeks. Patients receive concurrent chemotherapy comprising
cisplatin IV on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and 29-33.
After completion of study therapy, patients are followed at 6 weeks.
Criteria for eligibility:
Criteria:
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
- Stage IIIA (N2) or IIIB disease
- Pathologic documentation of N2-3 mediastinal lymph nodes is encouraged but
not required if nodal size is ≥ 1.5 cm in largest diameter
- No stage IIIB disease with malignant pleural effusion or superior sulcus
tumor
- At least one measurable lesion as defined by Response Evaluation Criteria in Solid
Tumors
- Unresectable disease
- No known brain metastasis
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 3 months
- ANC ≥ 1,500/mm³
- Hemoglobin ≥ 9.0 g/dL (can be corrected by transfusion)
- Platelet count ≥ 100,000/mm³
- Creatinine < 1.5 mg/dL
- Total bilirubin < 2 times upper limit of normal (ULN)
- Transaminases < 3 times ULN
- Patient compliance and geographic proximity that allow adequate follow up
- No serious, uncontrolled systemic intercurrent illness (e.g., infections or poorly
controlled diabetes)
- No history of significant neurological or mental disorder, including seizures or
dementia
- No other malignancy within the past 5 years except carcinoma in situ of the cervix
or nonmelanoma skin cancer
- No active cardiac disease not controlled by therapy
- No myocardial infarction within the past 12 months
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy or radiotherapy for NSCLC
- No other concurrent systemic chemotherapy, investigational drug, or radiotherapy
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Yonsei Cancer Center at Yonsei University Medical Center
Address:
City:
Seoul
Zip:
120-752
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Joo-Hang Kim, MD
Phone:
+82-10-4507-6063
Email:
kjhang@yuhs.ac
Start date:
June 2007
Lead sponsor:
Agency:
Yonsei University
Agency class:
Other
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00616785